Comparative efficacy, safety, onset of immunity of homologous LSDV Live-attenuated Vaccines v/s Heterologous Goat Pox Virus (GTPV)

By Animal Health India Editorial Team

September 15, 2026

0

3

homologous-lumpy-skin-vaccine-vs-heterologous-gaot-pox-vaccine

Lumpy Skin Disease outbreaks are spreading across different states / provinces of India despite availability of 2 different prophylactic vaccines, and these are:

Homologous Lumy Skin Disease Live-Attenuated Vaccine and
Heterologous Goat Pox Vaccine which initially was extensively used around 5 years ago in India as no Homologous vaccine for Lumpy Skin Disease was developed / approved at that time

Now, since both these vaccines are commercially available – lets try and understand the comparative efficacy and safety profiles of both these vaccines, as under:

Homologous Lumpy Skin Disease Virus (LSDV) live-attenuated vaccines and heterologous Goat Pox Virus (GTPV) vaccines are the two primary choices for controlling LSD in cattle.

While both leverage the genomic sequence similarity across the Capripoxvirus genus, their immunological performance, safety profiles, and clinical protection differ significantly.

Comparative Evaluation Matrix

Parameter	Homologous LSDV Vaccine (e.g., Neethling strain, Lumpi-ProVacInd)	Heterologous GTPV Vaccine (e.g., Gorgan strain, Uttarkashi strain)
Protective Efficacy	Superior (85%–100%) Induces robust, pathogen-specific neutralizing antibodies and a strong CD8+ T-cell response. Confers solid sterilizing/clinical protection.	Variable to Moderate (20%–80%) Efficacy depends heavily on the strain. Gorgan GTPV provides strong cross-protection, whereas other strains (e.g., Uttarkashi) may offer limited field protection without higher dosing.
Onset of Immunity	Rapid (10–14 days) Specific viral surface antigens trigger early cell-mediated immunity (CMI) and rapid seroconversion, making it ideal for ring vaccination during active outbreaks.	Slower (14–21+ days) Requires a longer window to build effective cross-reactive cellular responses. High antigenic challenge required for protection.
Duration of Immunity	Long-lasting (≥ 12–18 months) Single annual immunization maintains strong memory T-cell populations and sustained antibody titers.	Shorter / Waning (6–12 months) Cross-reactive immunity wanes faster, particularly in younger cattle (<12 months), often requiring booster doses at 4–6 months.
Safety & Post-Vaccine Complications	Moderate to Good Some classic Neethling strains cause a mild “Neethling response” (transient fever, temporary milk drop, small local nodules in ~1%–10% of herd). Next-gen variants (e.g., Lumpi-ProVacInd) show minimal to no side effects.	High Safety Profile Very low reactogenicity in cattle. Does not induce “Neethling-like” systemic disease or severe milk drops, as the virus is poorly adapted to replication in bovine tissues.
Dosing Requirements	Standard Single Dose Conforms to standard viral titers ( $10^{3.5} \text{ TCID}_{50}$ $10^{3.5} \text{ to } 10^{4.0} \text{ TCID}_{50}$ $10^{3.5} \text{ TCID}_{50}$ ).	Higher Dosing Required Usually requires 2× to 10× the standard goat dose ( $10^{3.5} \text{ to } 10^{4.0} \text{ TCID}_{50}$ ) when administered to cattle to compensate for heterologous antigenicity.

Parameter

Homologous LSDV Vaccine (e.g., Neethling strain, Lumpi-ProVacInd)

Heterologous GTPV Vaccine (e.g., Gorgan strain, Uttarkashi strain)

Protective Efficacy

Superior (85%–100%)

Induces robust, pathogen-specific neutralizing antibodies and a strong CD8+ T-cell response. Confers solid sterilizing/clinical protection.

Variable to Moderate (20%–80%)

Efficacy depends heavily on the strain. Gorgan GTPV provides strong cross-protection, whereas other strains (e.g., Uttarkashi) may offer limited field protection without higher dosing.

Onset of Immunity

Rapid (10–14 days)

Specific viral surface antigens trigger early cell-mediated immunity (CMI) and rapid seroconversion, making it ideal for ring vaccination during active outbreaks.

Slower (14–21+ days)

Requires a longer window to build effective cross-reactive cellular responses. High antigenic challenge required for protection.

Duration of Immunity

Long-lasting (≥ 12–18 months)

Single annual immunization maintains strong memory T-cell populations and sustained antibody titers.

Shorter / Waning (6–12 months)

Cross-reactive immunity wanes faster, particularly in younger cattle (<12 months), often requiring booster doses at 4–6 months.

Safety & Post-Vaccine Complications

Moderate to Good

Some classic Neethling strains cause a mild “Neethling response” (transient fever, temporary milk drop, small local nodules in ~1%–10% of herd). Next-gen variants (e.g., Lumpi-ProVacInd) show minimal to no side effects.

High Safety Profile

Very low reactogenicity in cattle. Does not induce “Neethling-like” systemic disease or severe milk drops, as the virus is poorly adapted to replication in bovine tissues.

Dosing Requirements

Standard Single Dose

Conforms to standard viral titers ( $10^{3.5} \text{ TCID}_{50}$ $10^{3.5} \text{ to } 10^{4.0} \text{ TCID}_{50}$ $10^{3.5} \text{ TCID}_{50}$ ).

Higher Dosing Required

Usually requires 2× to 10× the standard goat dose ( $10^{3.5} \text{ to } 10^{4.0} \text{ TCID}_{50}$ ) when administered to cattle to compensate for heterologous antigenicity.

Key Takeaways

Efficacy & Field Control: Homologous vaccines provide broader herd protection, preventing viral shedding and clinical disease far more consistently than heterologous strains. Countries facing severe epizootic outbreaks generally phase out GTPV in favor of homologous vaccines once domestic production scales up
Emergency Availability: Heterologous GTPV vaccines serve as an accessible emergency tool when homologous supplies are scarce, as GTPV manufacturing is already widespread in endemic sheep and goat farming regions
Safety Considerations: Where milk yield stability and low post-vaccination reactions are paramount, heterologous GTPV vaccines offer a gentle safety profile. However, newer homologous strains have significantly mitigated safety concerns while retaining maximum efficacy

Comparative efficacy, safety, onset of immunity of homologous LSDV Live-attenuated Vaccines v/s Heterologous Goat Pox Virus (GTPV)

Lumpy Skin Disease outbreaks are spreading across different states / provinces of India despite availability of 2 different prophylactic vaccines, and these are:

Homologous Lumy Skin Disease Live-Attenuated Vaccine and

Heterologous Goat Pox Vaccine which initially was extensively used around 5 years ago in India as no Homologous vaccine for Lumpy Skin Disease was developed / approved at that time

Now, since both these vaccines are commercially available – lets try and understand the comparative efficacy and safety profiles of both these vaccines, as under:

Homologous Lumpy Skin Disease Virus (LSDV) live-attenuated vaccines and heterologous Goat Pox Virus (GTPV) vaccines are the two primary choices for controlling LSD in cattle.

While both leverage the genomic sequence similarity across the Capripoxvirus genus, their immunological performance, safety profiles, and clinical protection differ significantly.

Comparative Evaluation Matrix

Parameter

Homologous LSDV Vaccine (e.g., Neethling strain, Lumpi-ProVacInd)

Heterologous GTPV Vaccine (e.g., Gorgan strain, Uttarkashi strain)

Protective Efficacy

Superior (85%–100%)

Induces robust, pathogen-specific neutralizing antibodies and a strong CD8+ T-cell response. Confers solid sterilizing/clinical protection.

Variable to Moderate (20%–80%)

Efficacy depends heavily on the strain. Gorgan GTPV provides strong cross-protection, whereas other strains (e.g., Uttarkashi) may offer limited field protection without higher dosing.

Onset of Immunity

Rapid (10–14 days)

Specific viral surface antigens trigger early cell-mediated immunity (CMI) and rapid seroconversion, making it ideal for ring vaccination during active outbreaks.

Slower (14–21+ days)

Requires a longer window to build effective cross-reactive cellular responses. High antigenic challenge required for protection.

Duration of Immunity

Long-lasting (≥ 12–18 months)

Single annual immunization maintains strong memory T-cell populations and sustained antibody titers.

Shorter / Waning (6–12 months)

Cross-reactive immunity wanes faster, particularly in younger cattle (<12 months), often requiring booster doses at 4–6 months.

Safety & Post-Vaccine Complications

Moderate to Good

Some classic Neethling strains cause a mild “Neethling response” (transient fever, temporary milk drop, small local nodules in ~1%–10% of herd). Next-gen variants (e.g., Lumpi-ProVacInd) show minimal to no side effects.

High Safety Profile

Very low reactogenicity in cattle. Does not induce “Neethling-like” systemic disease or severe milk drops, as the virus is poorly adapted to replication in bovine tissues.

Dosing Requirements

Standard Single Dose

Conforms to standard viral titers (10^3.5, TCID50).

Higher Dosing Required

Usually requires 2× to 10× the standard goat dose (10^3.5 to 10^4.0, TCID50) when administered to cattle to compensate for heterologous antigenicity.

Key Takeaways

Emergency Availability: Heterologous GTPV vaccines serve as an accessible emergency tool when homologous supplies are scarce, as GTPV manufacturing is already widespread in endemic sheep and goat farming regions

Safety Considerations: Where milk yield stability and low post-vaccination reactions are paramount, heterologous GTPV vaccines offer a gentle safety profile. However, newer homologous strains have significantly mitigated safety concerns while retaining maximum efficacy

UK Bluetongue Cases Surge Past 1,100 as Farmers Face Ugent Vaccination Call

INDIA: Himachal Pradesh Battles Lumpy Skin Disease Outbreaks

Badri Cattle OPU-IVF Breakthrough in India: Protocol, Surrogacy & Conservation of Indigenous Breed

Conforms to standard viral titers ( $10^{3.5} \text{ TCID}_{50}$ $10^{3.5} \text{ to } 10^{4.0} \text{ TCID}_{50}$ $10^{3.5} \text{ TCID}_{50}$ ).

Usually requires 2× to 10× the standard goat dose ( $10^{3.5} \text{ to } 10^{4.0} \text{ TCID}_{50}$ ) when administered to cattle to compensate for heterologous antigenicity.